Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genisphere, provider of the 3DNA drug delivery platform, has executed a collaborative research and option to license agreement with MedImmune, the global biologics research and development arm of AstraZeneca.
Subscribe to our email newsletter
Under the agreement, MedImmune and Genisphere will develop novel nanoparticles utilizing its 3DNA dendrimer scaffold with up to six MedImmune oncology molecules, as the nanoparticle configuration may help to improve targeting of the drug.
According to the agreement, Genisphere will receive an upfront payment, development milestones and future royalties upon MedImmune triggering an option, and development and commercialization of therapeutics stemming from the collaboration. No additional financial terms of the agreement were disclosed.
The agreement announced today is the creation of a formal partnership between the companies following a two-year R&D collaboration to customize 3DNA nanoparticles for various applications at MedImmune.
Tom Bliss, Genisphere’s Chief Executive Officer, said, "We have been very impressed with the forward thinking and highly collaborative nature of our partners at MedImmune and their willingness to explore novel ways to deliver novel oncology therapeutics. I am confident the flexibility of the 3DNA platform will help ensure success."
Genisphere will attend partnering sessions at the BIO international convention in San Francisco from June 6-9 to expand collaborations using the 3DNA platform for targeted drug delivery.